Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

• Status: Withdrawn
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Clostridium difficle infection is the leading cause of hospital acquired infection and infectious diarrhea in hospitalized patients. Eradication treatment for this infection is the challenging tasks for clinicians due to treatment resistance developed from new hypervirulent strains. The recurrence rate of this infection is around 20% and there is high likelihood(60-70%) of another episode after index recurrence. Given constant challenge new treatment options are under study. Aim of the study is to evaluate if use of bismuth subsalicylate (BSS) can decrease the length of stay in patients admitted with Clostridium difficile infection. Secondarily investigators will also see if there is any impact of BSS in decrease the recurrence.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bassett Healthcare
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Bismuth; Bismuth subsalicylate

Criteria

Inclusion Criteria:

• Age 18 or older

• Hospitalized patient with documented positive stool test for CDiff

• Able and willing to provide informed consent

Exclusion Criteria:

• Pregnancy

• Breastfeeding

• Known allergy to BSS or other salicylates, including aspirin

• History of bleeding disorder

• History of gastrointestinal bleed,

• History of gastrointestinal ulcer

• Chronic use of anticoagulants

• Chronic NSAID use